A more comprehensive dataset on JANX007 sends the group’s stock down.
ApexOnco Front Page
Recent articles
But the group still hopes to get IGV-001 approved based on overall survival data.
But Enhertu is coming.
The private biotech adds another asset to J&J’s prostate cancer pipeline.
The restructured biotech’s new lead project enters phase 1.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
The company will imminently start its third pivotal trial of PF-08634404.
